$CRDF
Cardiff Oncology, Inc.

2021 Q2 Form 10-Q Financial Statement

#000162828021015834 Filed on August 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $68.00K $43.00K
YoY Change 58.14% 12.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.838M $1.669M
YoY Change 70.04% 16.88%
% of Gross Profit
Research & Development $4.119M $2.476M
YoY Change 66.36% -12.52%
% of Gross Profit
Depreciation & Amortization $108.0K $110.0K
YoY Change -1.82% 175.0%
% of Gross Profit
Operating Expenses $6.957M $4.145M
YoY Change 67.84% -2.66%
Operating Profit -$6.889M -$4.102M
YoY Change 67.94% -2.8%
Interest Expense $132.0K -$30.00K
YoY Change -540.0%
% of Operating Profit
Other Income/Expense, Net $132.0K $6.000K
YoY Change 2100.0% 442.5%
Pretax Income -$6.757M -$4.120M
YoY Change 64.0% -0.24%
Income Tax
% Of Pretax Income
Net Earnings -$6.757M -$4.124M
YoY Change 63.85% -0.03%
Net Earnings / Revenue -9936.76% -9590.7%
Basic Earnings Per Share -$0.17 -$0.51
Diluted Earnings Per Share -$0.17 -$0.51
COMMON SHARES
Basic Shares Outstanding 38.76M shares 14.49M shares
Diluted Shares Outstanding 38.76M shares 14.49M shares

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $140.1M $27.80M
YoY Change 403.78% 157.41%
Cash & Equivalents $10.58M $27.80M
Short-Term Investments $129.5M
Other Short-Term Assets $2.512M $1.000M
YoY Change 151.2% 11.11%
Inventory
Prepaid Expenses $2.512M $955.0K
Receivables $308.0K $109.3K
Other Receivables $0.00 $0.00
Total Short-Term Assets $142.9M $28.82M
YoY Change 395.75% 143.82%
LONG-TERM ASSETS
Property, Plant & Equipment $422.0K $655.4K
YoY Change -35.61% 160.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $263.0K $152.6K
YoY Change 72.36% 12.81%
Total Long-Term Assets $863.0K $1.310M
YoY Change -34.11% -36.04%
TOTAL ASSETS
Total Short-Term Assets $142.9M $28.82M
Total Long-Term Assets $863.0K $1.310M
Total Assets $143.7M $30.13M
YoY Change 377.06% 117.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $543.0K $1.156M
YoY Change -53.01% 119.81%
Accrued Expenses $3.592M $2.858M
YoY Change 25.68% 21.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K
YoY Change
Total Short-Term Liabilities $4.579M $4.962M
YoY Change -7.72% 34.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $200.0K
YoY Change -100.0%
Other Long-Term Liabilities $214.0K $72.70K
YoY Change 194.36% -94.41%
Total Long-Term Liabilities $214.0K $72.70K
YoY Change 194.36% -94.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.579M $4.962M
Total Long-Term Liabilities $214.0K $72.70K
Total Liabilities $4.816M $5.745M
YoY Change -16.17% 14.45%
SHAREHOLDERS EQUITY
Retained Earnings -$243.4M -$220.4M
YoY Change 10.46% 9.92%
Common Stock $4.000K $9.585K
YoY Change -58.27% 19.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $138.9M $24.38M
YoY Change
Total Liabilities & Shareholders Equity $143.7M $30.13M
YoY Change 377.06% 117.26%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$6.757M -$4.124M
YoY Change 63.85% -0.03%
Depreciation, Depletion And Amortization $108.0K $110.0K
YoY Change -1.82% 175.0%
Cash From Operating Activities -$4.305M -$4.300M
YoY Change 0.12% 25.0%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$19.00M
YoY Change
Cash From Investing Activities -$19.00M $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.23M 22.77M
YoY Change -15.56% 682.47%
NET CHANGE
Cash From Operating Activities -4.305M -4.300M
Cash From Investing Activities -19.00M 0.000
Cash From Financing Activities 19.23M 22.77M
Net Change In Cash -4.080M 18.47M
YoY Change -122.09% -3584.91%
FREE CASH FLOW
Cash From Operating Activities -$4.305M -$4.300M
Capital Expenditures $0.00
Free Cash Flow -$4.300M
YoY Change 25.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001213037
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39552129 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35558
dei Entity Registrant Name
EntityRegistrantName
CARDIFF ONCOLOGY, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-2004382
dei Entity Address Address Line1
EntityAddressAddressLine1
11055 Flintkote Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
952-7570
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
CRDF
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10581000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
130981000 USD
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
129470000 USD
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
308000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
320000 USD
CY2021Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2512000 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2055000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
142871000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
133356000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
422000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
343000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
624000 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
178000 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
263000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
404000 USD
CY2021Q2 us-gaap Assets
Assets
143734000 USD
CY2020Q4 us-gaap Assets
Assets
134727000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
543000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1366000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3592000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3851000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
402000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
860000 USD
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
42000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
42000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4579000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-243443000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6119000 USD
CY2021Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
17000 USD
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
285000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9000 USD
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
214000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
156000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
4816000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
6569000 USD
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
1000 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
1000 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39552000 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39552000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36781000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36781000 shares
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
383611000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
361819000 USD
CY2021Q2 crdf Servicereceivable
Servicereceivable
1245000 USD
CY2020Q4 crdf Servicereceivable
Servicereceivable
2171000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-231495000 USD
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2838000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
138918000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
128158000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
143734000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
134727000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
68000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
43000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
140000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
110000 USD
CY2021Q2 us-gaap Revenues
Revenues
68000 USD
CY2020Q2 us-gaap Revenues
Revenues
43000 USD
us-gaap Revenues
Revenues
140000 USD
us-gaap Revenues
Revenues
110000 USD
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4119000 USD
CY2020Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2476000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7398000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5181000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1669000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5073000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3155000 USD
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
6957000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
4145000 USD
us-gaap Operating Expenses
OperatingExpenses
12471000 USD
us-gaap Operating Expenses
OperatingExpenses
8336000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6889000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4102000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-12331000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-8226000 USD
CY2021Q2 us-gaap Interest Income Operating
InterestIncomeOperating
71000 USD
CY2020Q2 us-gaap Interest Income Operating
InterestIncomeOperating
16000 USD
us-gaap Interest Income Operating
InterestIncomeOperating
115000 USD
us-gaap Interest Income Operating
InterestIncomeOperating
51000 USD
CY2021Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
61000 USD
CY2020Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-44000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
268000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-42000 USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6757000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4124000 USD
us-gaap Net Income Loss
NetIncomeLoss
-11936000 USD
us-gaap Net Income Loss
NetIncomeLoss
-8213000 USD
CY2021Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6000 USD
CY2020Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
12000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
12000 USD
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6763000 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7397000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11948000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11492000 USD
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.94
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.94
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38761000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38761000 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14492000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14492000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37967000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37967000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12201000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12201000 shares
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6757000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4124000 USD
us-gaap Net Income Loss
NetIncomeLoss
-11936000 USD
us-gaap Net Income Loss
NetIncomeLoss
-8213000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
57000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-10000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6700000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4124000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11946000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8213000 USD
CY2021Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6000 USD
CY2020Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
12000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
12000 USD
CY2021Q2 crdf Comprehensive Income Loss Availableto Common Stockholders Basic
ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic
-6706000 USD
CY2020Q2 crdf Comprehensive Income Loss Availableto Common Stockholders Basic
ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic
-7397000 USD
crdf Comprehensive Income Loss Availableto Common Stockholders Basic
ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic
-11958000 USD
crdf Comprehensive Income Loss Availableto Common Stockholders Basic
ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic
-11492000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
128158000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
268000 USD
CY2021Q1 crdf Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1263000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-67000 USD
CY2021Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 USD
CY2021Q1 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
380000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5179000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
124817000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1036000 USD
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19225000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
57000 USD
CY2021Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 USD
CY2021Q2 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
546000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6757000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
138918000 USD
CY2021Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
800000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7310000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
177000 USD
CY2020Q1 crdf Sale Of Stock Value Common And Warrants Net
SaleOfStockValueCommonAndWarrantsNet
-1000000 USD
CY2020Q1 crdf Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1456000 USD
CY2020Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 USD
CY2020Q1 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
293000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4089000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
6141000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
282000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-8000 USD
CY2020Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
17279000 USD
CY2020Q2 crdf Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
4605000 USD
CY2020Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 USD
CY2020Q2 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
213000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4124000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
24382000 USD
CY2020Q2 crdf Costof Issuanceof Common Stock Preferred Stockand Warrantsfor Clinical Trial Funding Commitment
CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment
600000 USD
CY2020Q2 crdf Warrants Fair Value
WarrantsFairValue
400000 USD
us-gaap Net Income Loss
NetIncomeLoss
-11936000 USD
us-gaap Net Income Loss
NetIncomeLoss
-8213000 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-1000 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0 USD
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
34000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
228000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
234000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1304000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
459000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-698000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
268000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-42000 USD
crdf Releaseofclinicaltrialfundingcommitmentforservicesreceived
Releaseofclinicaltrialfundingcommitmentforservicesreceived
926000 USD
crdf Releaseofclinicaltrialfundingcommitmentforservicesreceived
Releaseofclinicaltrialfundingcommitmentforservicesreceived
506000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-141000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-5000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-12000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-94000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-68000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
0 USD
crdf Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-165000 USD
crdf Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-161000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1121000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-513000 USD
crdf Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-461000 USD
crdf Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-418000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
58000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-56000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10185000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7665000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
5510000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
0 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
141948000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
5735000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-130703000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
776000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
93000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19225000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18802000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-8000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1263000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6126000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
305000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20488000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25225000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-120400000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
17560000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
130981000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10195000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10581000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27755000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
27000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
11000 USD
crdf Stock Issuance Costs Incurred But Not Yet Paid
StockIssuanceCostsIncurredButNotYetPaid
0 USD
crdf Stock Issuance Costs Incurred But Not Yet Paid
StockIssuanceCostsIncurredButNotYetPaid
523000 USD
crdf Warrant Exercise Costs Incurred But Not Yet Paid
WarrantExerciseCostsIncurredButNotYetPaid
0 USD
crdf Warrant Exercise Costs Incurred But Not Yet Paid
WarrantExerciseCostsIncurredButNotYetPaid
64000 USD
crdf Preferred Stock Dividend Accrued
PreferredStockDividendAccrued
12000 USD
crdf Preferred Stock Dividend Accrued
PreferredStockDividendAccrued
12000 USD
CY2021Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
140100000 USD
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6763000 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-7397000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11948000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11492000 USD
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38761000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38761000 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14492000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14492000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37967000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37967000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12201000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12201000 shares
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
129480000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
16000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
26000 USD
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.94
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.94
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10142486 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17805051 shares
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3640000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
129470000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3628000 USD
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3218000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3004000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
422000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
624000 USD
crdf Lessor Number Of Subleases
LessorNumberOfSubleases
3 lease
crdf Lessee Operating Lease Monthly Rent Payment
LesseeOperatingLeaseMonthlyRentPayment
80000 USD
crdf Lessee Operating Lease Annual Rent Increase Percentage
LesseeOperatingLeaseAnnualRentIncreasePercentage
0.03
crdf Lessee Operating Lease Area Of Lease
LesseeOperatingLeaseAreaOfLease
26100 sqft
crdf Lessor Number Of Subleases
LessorNumberOfSubleases
3 lease
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
92000 USD
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
139000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
187000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
246000 USD
CY2021Q2 us-gaap Sublease Income
SubleaseIncome
101000 USD
CY2020Q2 us-gaap Sublease Income
SubleaseIncome
73000 USD
us-gaap Sublease Income
SubleaseIncome
202000 USD
us-gaap Sublease Income
SubleaseIncome
146000 USD
CY2021Q2 us-gaap Lease Cost
LeaseCost
-9000 USD
CY2020Q2 us-gaap Lease Cost
LeaseCost
66000 USD
us-gaap Lease Cost
LeaseCost
-15000 USD
us-gaap Lease Cost
LeaseCost
100000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
483000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
469000 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
178000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
343000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
402000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
860000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9000 USD
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
408000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
869000 USD
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y6M
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
243000 USD
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
236000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
406000 USD
CY2021Q2 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
202000 USD
CY2021Q2 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear
204000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6000 USD
CY2021Q2 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
0 USD
CY2021Q2 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year One
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne
6000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3000 USD
CY2021Q2 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
0 USD
CY2021Q2 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Two
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo
3000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
415000 USD
CY2021Q2 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
202000 USD
CY2021Q2 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Due
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue
213000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7000 USD
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
408000 USD
crdf Class Of Warrant Or Right Number Exercised
ClassOfWarrantOrRightNumberExercised
770833 shares
crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised
1.64
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1036000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
282000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1304000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
459000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1200000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
800000 USD
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4490159 shares
CY2021Q2 crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
5.80
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2886407 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.72
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
7262361 USD
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3150000 shares
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5260992 shares
CY2020Q4 crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
5.19
CY2021Q1 crdf Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights
ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
P4Y1M6D
crdf Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights
ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
P3Y6M
CY2021Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
2000000.0 shares

Files In Submission

Name View Source Status
0001628280-21-015834-index-headers.html Edgar Link pending
0001628280-21-015834-index.html Edgar Link pending
0001628280-21-015834.txt Edgar Link pending
0001628280-21-015834-xbrl.zip Edgar Link pending
a102ex080521.htm Edgar Link pending
crdf-063021exhibit311.htm Edgar Link pending
crdf-063021exhibit312.htm Edgar Link pending
crdf-063021exhibit321.htm Edgar Link pending
crdf-063021exhibit322.htm Edgar Link pending
crdf-20210630.htm Edgar Link pending
crdf-20210630.xsd Edgar Link pending
crdf-20210630_cal.xml Edgar Link unprocessable
crdf-20210630_def.xml Edgar Link unprocessable
crdf-20210630_htm.xml Edgar Link completed
crdf-20210630_lab.xml Edgar Link unprocessable
crdf-20210630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending